OBJECTIVES: We have evaluated the recently Conformité Européenne (CE)-marked Bio-Rad Geenius human immunodeficiency virus (HIV)1/2 as a rapid and simple alternative to western blot for confirmation of HIV screening results. METHODS: A total of 160 serum samples were tested: 44 HIV-1 reactive samples by a fourth-generation Murex HIV Ag/Ab and/or Vidas HIV Duo Ultra, five HIV-2 reactive samples, 15 HIV-1 non-B subtype samples and 11 confirmed HIV-1 early seroconversion samples, 72 nonreactive samples, eight indeterminate samples by MP HIV BLOT 2.2 confirmed negative after follow-up and five low-reactive samples by enzyme immunoassay (EIA) negative by MP HIV BLOT 2.2. The samples were tested according to the manufacturer's guidelines. RESULTS: The overall sensitivity for Bio-Rad Geenius HIV1/2 assay was 92%. Five out of 11 early seroconversion samples were tested positive, four negative and two indeterminate. All HIV-1 non-B subtype samples were tested positive. Two out of the five HIV-2 reactive samples were tested positive HIV-2, two positive HIV-2 with HIV-1 cross-reaction and one HIV positive untypable. After excluding early seroconversion samples, the sensitivity of Bio-Rad Geenius HIV1/2 assay reached 100%. Overall specificity was 96%. All HIV negative serums by fourth-generation EIA were tested negative. All five low-reactive samples by EIA, negative by HIV BLOT 2.2 were tested negative by Bio-Rad Geenius HIV1/2. Two out of the eight indeterminate samples by MP HIV BLOT 2.2 that were confirmed negative after follow-up were tested indeterminate and one invalid, the other five were negative. After excluding these last 13 samples, the specificity of Bio-Rad Geenius HIV1/2 assay reached 100%. In comparison with MP HIV BLOT 2.2, the Bio-Rad Geenius HIV1/2 assay was markedly time saving, allowed full traceability, automatic reading and interpretation. CONCLUSIONS: The Bio-Rad Geenius HIV1/2 confirmatory system represents a reliable alternative to other confirmatory assays in HIV testing algorithms and provides clear improvement in quality management.
OBJECTIVES: We have evaluated the recently Conformité Européenne (CE)-marked Bio-Rad Geenius human immunodeficiency virus (HIV)1/2 as a rapid and simple alternative to western blot for confirmation of HIV screening results. METHODS: A total of 160 serum samples were tested: 44 HIV-1 reactive samples by a fourth-generation Murex HIV Ag/Ab and/or Vidas HIV Duo Ultra, five HIV-2 reactive samples, 15 HIV-1 non-B subtype samples and 11 confirmed HIV-1 early seroconversion samples, 72 nonreactive samples, eight indeterminate samples by MP HIV BLOT 2.2 confirmed negative after follow-up and five low-reactive samples by enzyme immunoassay (EIA) negative by MP HIV BLOT 2.2. The samples were tested according to the manufacturer's guidelines. RESULTS: The overall sensitivity for Bio-Rad Geenius HIV1/2 assay was 92%. Five out of 11 early seroconversion samples were tested positive, four negative and two indeterminate. All HIV-1 non-B subtype samples were tested positive. Two out of the five HIV-2 reactive samples were tested positive HIV-2, two positive HIV-2 with HIV-1 cross-reaction and one HIV positive untypable. After excluding early seroconversion samples, the sensitivity of Bio-Rad Geenius HIV1/2 assay reached 100%. Overall specificity was 96%. All HIV negative serums by fourth-generation EIA were tested negative. All five low-reactive samples by EIA, negative by HIV BLOT 2.2 were tested negative by Bio-Rad Geenius HIV1/2. Two out of the eight indeterminate samples by MP HIV BLOT 2.2 that were confirmed negative after follow-up were tested indeterminate and one invalid, the other five were negative. After excluding these last 13 samples, the specificity of Bio-Rad Geenius HIV1/2 assay reached 100%. In comparison with MP HIV BLOT 2.2, the Bio-Rad Geenius HIV1/2 assay was markedly time saving, allowed full traceability, automatic reading and interpretation. CONCLUSIONS: The Bio-Rad Geenius HIV1/2 confirmatory system represents a reliable alternative to other confirmatory assays in HIV testing algorithms and provides clear improvement in quality management.
Authors: Reshma Kassanjee; Christopher D Pilcher; Michael P Busch; Gary Murphy; Shelley N Facente; Sheila M Keating; Elaine Mckinney; Kara Marson; Matthew A Price; Jeffrey N Martin; Susan J Little; Frederick M Hecht; Esper G Kallas; Alex Welte Journal: AIDS Date: 2016-09-24 Impact factor: 4.177
Authors: Sharon M Coleman; Natalia Gnatienko; Christine A Lloyd-Travaglini; Michael R Winter; Carly Bridden; Elena Blokhina; Dmitry Lioznov; Julian Adong; Jeffrey H Samet; Teri Liegler; Judith A Hahn Journal: HIV Clin Trials Date: 2018-01-31
Authors: Dana Duncan; John Duncan; Bastian Kramer; Alex Y Nilsson; Betiel Haile; Ann Butcher; Shikha Chugh; Paul Baum; Grace M Aldrovandi; Stephen Young; Ann K Avery; Karen Tashima; Alexandra Valsamakis; Joseph D Yao; Ming Chang; Robert W Coombs Journal: J Clin Microbiol Date: 2021-06-18 Impact factor: 5.948
Authors: Hee-Won Moon; Hee Jin Huh; Gwi Young Oh; Sang Gon Lee; Anna Lee; Yeo-Min Yun; Mina Hur Journal: PLoS One Date: 2015-09-30 Impact factor: 3.240
Authors: Charles S Morrison; Rick Homan; Natasha Mack; Pairin Seepolmuang; Megan Averill; Jamilah Taylor; Jennifer Osborn; Peter Dailey; Neil Parkin; Stefano Ongarello; Timothy D Mastro Journal: J Int AIDS Soc Date: 2017-11 Impact factor: 5.396
Authors: Sheila M Keating; Reshma Kassanjee; Mila Lebedeva; Shelley N Facente; Jeffrey C MacArthur; Eduard Grebe; Gary Murphy; Alex Welte; Jeffrey N Martin; Susan Little; Matthew A Price; Esper G Kallas; Michael P Busch; Christopher D Pilcher Journal: J Acquir Immune Defic Syndr Date: 2016-12-15 Impact factor: 3.731